Castle Biosciences Inc CSTL

US Health Care

$28.00 ▲ +4.52% (+$1.21)

⬆️ Above Yest. High ⚡ High Volume

Open $28.75

Prev Close $26.79

Day Range $27.50 – $30.81

52W Range $14.59 – $44.28

Market Cap $849.24M

Beta 1.01

EPS (TTM) $-0.43

📋 Company Profile

Industry	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2019-07-25
Shares Out.	30,330,000
Website	castlebiosciences.com/ ↗
Phone	13026365400
Employees	942
Revenue	$83.7M
Gross Profit	$63.1M
Net Income	-$14.5M
Free Cash Flow	$4.5M
Total Assets	$547.8M
Total Liabilities	$86.4M
Equity	$461.4M

About Castle Biosciences Inc

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Castle Biosciences Inc is a publicly traded company under the ticker symbol CSTL on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.